
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Frederick L. Locke, MD, discusses the results from the ZUMA-7 clinical trial that focused on axicabtagene ciloleucel, as presented at the 63rd ASH Annual Meeting in 2021.
OncLive® Rapid Readout from Primary Analysis of ZUMA‑7: a Phase 3 Randomized Trial of Axicabtagene Ciloleucel versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B‐Cell Lymphoma
Segment Description: Frederick L. Locke, MD, discusses the results from the ZUMA-7 clinical trial that focused on axicabtagene ciloleucel, as presented at the 63rd ASH Annual Meeting in 2021. (
Segment Body Content:
Methods
Results
Conclusions






